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Abstract
Background: The use of post-transplant cyclophosphamide (PTCy) is highly effective in preventing graft-versus-host
disease (GVHD) in the haploidentical (Haplo) transplant setting and is being increasingly used in matched sibling
(MSD) and matched unrelated (MUD) transplants. There is no information on the impact of donor types using
homogeneous prophylaxis with PTCy.
Methods: We retrospectively compared outcomes of adult patients with acute myeloid leukemia (AML) in first
complete remission (CR1) who received a first allogeneic stem cell transplantation (SCT) with PTCy as GVHD
prophylaxis from MSD (n = 215), MUD (n = 235), and Haplo (n = 789) donors registered in the EBMT database
between 2010 and 2017.
Results: The median follow-up was 2 years. Haplo-SCT carried a significantly increased risk of acute grade II–IV
GVHD (HR 1.6; 95% CI 1.1–2.4) and NRM (HR 2.6; 95% CI 1.5–4.5) but a lower risk of relapse (HR 0.7; 95% CI 0.5–0.9)
that translated to no differences in LFS (HR 1.1; 95% CI 0.8–1.4) or GVHD/relapse-free survival (HR 1; 95% CI 0.8–1.3).
Interestingly, the use of peripheral blood was associated with an increased risk of acute (HR 1.9; 95% CI 1.4–2.6) and
chronic GVHD (HR 1.7; 95% CI 1.2–2.4) but a lower risk of relapse (HR 0.7; 95% CI 0.5–0.9).
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Conclusions: The use of PTCy in patients with AML in CR1 receiving SCT from MSD, MUD, and Haplo is safe and
effective. Haplo-SCT had increased risk of acute GVHD and NRM and lower relapse incidence but no significant
difference in survival.
Keywords: Post-transplant cyclophosphamide, Haploidentical transplant, Alternative donor transplants, Acute
leukemia, Allogeneic stem cell transplant
Introduction
The use of post-transplant cyclophosphamide (PTCy)
has proven to be highly effective in preventing graft-
versus-host (GVHD) and reducing non-relapse mortality
(NRM) rates in haploidentical (Haplo) hematopoietic
stem cell transplant (SCT) [1–3].
As a consequence, PTCy is being increasingly used in
other allogeneic transplant settings, such as SCT from
HLA-matched sibling donors (MSD) [4–6], matched un-
related donors (MUD), and mismatched unrelated do-
nors (MMUD) [1–3, 7].
Since the first reports of Haplo-SCT using PTCy, there
has been significant interest in comparing this platform
with those using other donor types such as cord blood
from unrelated donors [4–6, 8] or bone marrow (BM) or
peripheral blood (PB) from MSD, MUD, and MMUD
transplants [9–15]. However, an important limitation of
these studies is that each type of transplant received dif-
ferent GVHD prophylaxis. Therefore, comparisons were
made of different transplant platforms instead of differ-
ent donor types. Two prospective studies compared T
cell replete Haplo and MSD transplants in acute myeloid
leukemia (AML) [16] and acute lymphoblastic leukemia
[17] using non-PTCy GVHD prophylaxis with similar re-
sults but increased risk of GVHD after Haplo. In
addition, safety and feasibility of PTCy-based GVHD
prophylaxis in transplants using different donor types
was further evaluated in small single-center prospective
non-randomized studies showing comparable outcomes
in Haplo-SCT compared to 9/10 MUD [18], as well as in
MSD, MUD, and MMUD transplants [19].
The aim of this study was to investigate the impact of
donor type in the outcome of patients with AML under-
going unmanipulated allogeneic SCT (allo-SCT) using
PTCy as GvHD prophylaxis. We analyzed patients who
received allo-SCT from MSD, MUD, and Haplo for
acute myeloid leukemia (AML) in first complete remis-
sion (CR1) and reported to the European Society for
Blood and Marrow Transplantation (EBMT) registry
from 2010 to 2017.
Patients and methods
Study design and data source
This is a retrospective registry-based analysis on behalf
of the Acute Leukaemia Working Party (ALWP) of the
EBMT. The EBMT is a voluntary working group of
more than 600 transplantation centers that are required
to report all consecutive stem cell transplantations and
follow-up once a year. Audits are routinely performed to
determine the accuracy of the data. All transplantation
centers are required to obtain written informed consent
before data registration with the EBMT in accordance
with the 1975 Helsinki Declaration.
Patient eligibility
All adults (age ≥ 18 years) with AML in CR1 at trans-
plantation, reported to Promise-EBMT, who underwent
first allogeneic SCT, from an unmanipulated graft, using
PT-Cy from Haplo, MUD, or MSD donors between
2010 and 2017, were analyzed. Haplo was defined as
recipient-donor number of human leukocyte antigen
(HLA) mismatches ≥ 2.
Endpoints and definitions
The primary endpoint was to compare leukemia-free sur-
vival (LFS) after MSD, MUD, and Haplo donor trans-
plants. Secondary endpoints were neutrophil engraftment,
acute GVHD (aGVHD) and chronic GVHD (cGVHD), re-
lapse incidence, nonrelapse mortality (NRM), GVHD-free
and relapse-free survival (GRFS), and overall survival (OS)
within the same subgroups and to perform analysis of risk
factors for each outcome.
Neutrophil recovery was defined as the first day of an
absolute neutrophil count of 0.5 × 109/L lasting for 3 or
more consecutive days. aGVHD and cGVHD were de-
fined and graded according to standard criteria [20, 21].
Relapse was defined as disease recurrence and appear-
ance of blasts in the peripheral blood or BM (> 5%) after
CR. LFS was calculated until the date of first relapse,
death from any cause, or the last follow-up for patients
in CR. NRM was defined as death from any cause other
than relapse. The composite endpoint GRFS was defined
as survival without the following events: stage III–IV
aGVHD, severe cGVHD, disease relapse, or death from
any cause after SCT [22]. Myeloablative conditioning
(MAC) was defined as a regimen containing either total
body irradiation with a dose greater than 6 Gray, a total
dose of oral busulfan greater than 8 mg/kg, or a total
dose of intravenous busulfan > 6.4 mg/kg or melphalan
at doses > 140 mg/m2. In addition, regimens containing
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2 alkylating agents were considered as MAC. All other
regimens were defined as reduced intensity (RIC).
Statistical analysis
Patient characteristics according to donor type were
compared using chi-squared tests for categorical and
Kruskal-Wallis tests for continuous variables. GRFS,
LFS, and OS were estimated using the Kaplan-Meier
method. Cumulative incidence functions were used to
estimate neutrophil engraftment, aGVHD, cGVHD, re-
lapse incidence, and NRM. Competing risks were death
for relapse incidence and neutrophil engraftment, re-
lapse for NRM, and relapse or death for aGVHD and
cGVHD. Univariate analyses were done using the log-
rank test for LFS, GRFS, and OS and Gray’s test for cu-
mulative incidence. Multivariate analyses were per-
formed using the Cox proportional hazard model.
Donor type, gender, age at transplantation, perform-
ance status, cytogenetic risk group according to the
Medical Research Council [23], type of AML (primary vs
secondary) stem cell source, transplantation year, cyto-
megalovirus serostatus, and conditioning regimen were
included in the final model. To take into account the
center effect, we introduced a random effect (also named
frailty effect) for each center into the model. The signifi-
cance level was fixed at .05, and p values were 2-sided.
Statistical analyses were performed using R software ver-
sion 3.2.3 (R Development Core Team, Vienna, Austria)
software packages.
Results
Patient and transplantation characteristics
Patient, disease, and transplant characteristics of the
overall population and according to donor type are sum-
marized in Table 1. Briefly, a total of 1239 patients were
included in the study, of which 789 were transplanted
from Haplo, 235 from MUD, and 215 from MSD do-
nors. Median age of patients was 52 years (range, 18–
76). Forty-seven (6%), 543 (66%), and 239 (29%) had
standard-, intermediate-, and high-risk cytogenetics, re-
spectively. Preferred conditioning regimens were thio-
tepa, busulfan, and fludarabine for Haplo (n = 371; 47%)
and busulfan and fludarabine for MSD (n = 83; 39%)
and MUD (n = 102; 43%).
Haplo patients were older (p < 0.001) and had higher
proportion of secondary AML (p < 0.001), while differ-
ences in gender, performance status, and cytogenetic risk
category were not statistically significant. Regarding
transplant characteristics, Haplo-SCT recipients received
more frequently MAC (p = 0.006) and BM as stem cell
source (p < 0.001), while the proportion of in vivo T cell
depletion was higher in MUD transplants (p < 0.001).
Although the vast majority (93%) of Haplo patients re-
ceived GvHD prophylaxis with PTCy combined with 2
other immunosuppressive (IS) drugs, only 47% and 26%
of MUD and MSD patients received such combination,
respectively. In contrast, a higher proportion of MSD
and MUD patients received 1 or no additional IS drugs
than Haplo patients (p < 0.001).
Engraftment
Cumulative incidence of neutrophil recovery at 60 days
was 94% (95% CI; 92–95) for Haplo, 98% (95% CI; 95–
99) for MUDs, and 98% (95% CI; 94–99) for MSDs (p =
0.12). The median time of neutrophil recovery was 19
days (range, 2–63), 20 days (range, 2–48), and 19 days
(range, 5–64) for Haplo, MUD, and MSD, respectively.
GvHD
The cumulative incidence of aGvHD grades II–IV at 100
days was 26% (95% CI; 23–29) for Haplo, 28% (95% CI; 22–
34) for MUD, and 17% (95% CI; 12–23) for MSD (p =
0.03). The cumulative incidence of aGvHD grades III–IV
was 9% (95% CI; 7–12) for Haplo, 8% (95% CI; 5–11) for
MUD, and 6% (95% CI; 4–10) for MSD (p = 0.2) (Table 2).
In multivariable analysis (Table 3), Haplo was associated
with an increased risk of aGvHD grades II–IV, when com-
pared with MSD (HR 1.6; 95% CI, 1.08–2.37; p = 0.02). The
use of PB as the stem cell source was also associated
with a higher risk of aGvHD grades II–IV (HR 1.93;
95% CI, 1.39–2.67; p < 0.001) and grades III–IV (HR
1.86; 95% CI, 1.1–3.15; p = 0.02) (Table 4).
The cumulative incidence of cGvHD at 2 years was
30% (95% CI; 26–33), 32% (95% CI; 25–39), and 34%
(95% CI; 26–41) (p = 0.3) for Haplo, MUD, and MSD,
respectively (Table 2). The cumulative incidence of ex-
tensive type cGvHD was 10% (95% CI; 8–13) for Haplo,
18% (95% CI; 13–25) for MUD, and 14% (95% CI; 9–20)
for MSD (p = 0.003) (Table 2). In multivariable analysis
(Table 4), use of PB was independently associated with a
higher risk of cGvHD (HR 1.71; 95% CI, 1.23–2.39; p =
0.001) and extensive cGvHD (HR 1.86; 95% CI, 1.15–
3.01; p = 0.01). Female donor to male recipient showed
also an increased risk of extensive cGvHD (HR 1.71;
95% CI, 1.14–2.57; p = 0.009). Donor type was not asso-
ciated with the risk of cGvHD or extensive cGvHD in
multivariate analysis.
Relapse
The median time to relapse was 192 days (range, 3–1750).
The cumulative incidence of relapse at 2 years was 23%
(95% CI; 20–26) for Haplo, 25% (95% CI; 19–31) for MUD,
and 33% (95% CI; 26–41) for MSD (p = 0.02) (Table 2)
(Fig. 1). In multivariable analysis (Table 3), Haplo was asso-
ciated with a lower risk of relapse when compared with
MSD (HR 0.67; 95% CI, 0.48–0.93; p = 0.02). Other vari-
ables associated with a decreased risk of relapse were use of
MAC (HR 0.56; 95% CI, 0.43–0.77; p < 0.001), PB as the
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Table 1 Patient disease and transplant characteristics according to donor type
Characteristics Total
N = 1239
MSD
N = 215
MUD
N = 235
Haplo
N = 789
p
Age in years, median (range) 52 (18–75) 48 (18–71) 47 (18–74) 54 (18–75) < 0.001
Gender, n (%) 0.9
Male 693 (56) 117 (54) 132 (56) 444 (56)
Female 546 (44) 98 (46) 103 (44) 345 (44)
Karnofsky performance status, n (%) 0.2
≥ 90 929 (79) 159 (77) 192 (83) 578 (78)
< 90 251 (21) 48 (23) 39 (17) 164 (22)
Missing 59 8 4 47
Cytogenetic risk category, n (%) 0.2
Standard 47 (6) 10 (8) 8 (6) 29 (5)
Intermediate 543 (66) 92 (70) 87 (60) 364 (66)
High 239 (29) 29 (22) 49 (34) 161 (29)
Missing 410 84 91 235
Type of AML, n (%) < 0.001
De novo 1046 (84) 188 (87) 216 (92) 642 (81)
Secondary 193 (16) 27 (13) 19 (8) 147 (19)
Months from diagnosis to transplant, median (range) 5 (1-18) 4 (1-18) 5 (2-18) 5 (1-18) < 0.001
Conditioning intensity, n (%) 0.03
Myeloablative 725 (59) 122 (58) 116 (50) 487 (62)
Reduced intensity 500 (41) 87 (42) 115 (50) 298 (38)
Missing 14 6 4 4
Type of conditioning, n (%) 0.2
Based on chemotherapy 950 (77) 159 (75) 172 (75) 619 (78)
Based on TBI 287 (23) 54 (25) 63 (25) 170 (22)
Missing 2 2 0 0
Stem cell source, n (%) < 0.001
Bone marrow 425 (34) 62 (29) 22 (9) 341 (43)
Mobilized peripheral blood 814 (66) 152 (71) 213 (91) 448 (57)
In vivo T cell depletion, n (%) 164 (13) 29 (13) 63 (27) 72 (9) < 0.001
GvHD prophylaxis, n (%) < 0.001
PTCy + 2 drugs 897 (72) 56 (26) 111 (47) 730 (93)
PTCy + 1 drug 265 (21) 108 (50) 111 (47) 46 (6)
PTCy only 77 (6) 51 (24) 13 (6) 13 (2)
Donor-recipient gender combination, n (%) 0.02
Female donor to male recipient 249 (20) 54 (25) 34 (14) 161 (20)
Other combinations 988 (80) 161 (75) 201 (86) 626 (80)
Missing 2 0 0 2
Donor-recipient CMV serostatus, n (%) < 0.001
Negative-negative 181 (15) 33 (16) 49 (21) 99 (13)
Positive-negative 82 (7) 13 (6) 13 (6) 56 (7)
Negative-positive 248 (21) 17 (13) 73 (32) 148 (19)
Positive-positive 680 (57) 129 (64) 94 (41) 457 (60)
Missing 48 13 6 29
TBI total-body irradiation, CMV cytomegalovirus
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stem cell source (HR 0.74; 95% CI, 0.45–0.99; p = 0.04),
and standard or intermediate cytogenetic risk category (HR
0.58; 95% CI, 0.43–0.78; p < 0.001) (Table 4).
NRM and causes of death
The cumulative incidence of NRM at 2 years was 23%
(95% CI; 20–26) for Haplo, 14% (95% CI; 9–19) for
MUD, and 10% (95% CI; 6–15) for MSD (p < 0.001)
(Table 2) (Fig. 2). In multivariable analysis (Table 3),
Haplo was associated with an increased risk of NRM
(HR 2.6; 95% CI, 1.5–4.49; p < 0.001). The other factor
associated with an increased NRM was higher recipient’s
age per 10 years (HR 1.35; 95% CI, 1.19–1.54; p < 0.001)
(Table 4).
At the last follow-up, 432 patients had died, of which
290 (65%) were due to a variety of non-relapse causes,
222 (73%) in Haplo, 36 (52%) in MUD, and 32 (47%) in
MSD. The main causes of transplant-related deaths were
infections and GvHD, being 107 (39%) and 40 (14%) in
Haplo, 13 (20%) and 8 (12%) in MUD, and, 10 (15%) and
11 (16%) in MSD cohorts, respectively (Table 5).
Survival
For the entire cohort, LFS, OS, and GRFS at 2 years were
56% (95%CI; 53–59), 63% (95%CI; 60–66), and 45%
(95%CI; 42–48), respectively.
LFS was 54% (95% CI; 51–58) for Haplo, 62% (95% CI;
55–69) for MUD, and 57% (95% CI; 49–65) for MSD (p
= 0.2) (Fig. 3). In multivariable analysis (Table 4), vari-
ables associated with better LFS were MAC (HR 0.71;
95% CI, 0.58–0.88; p = 0.001), good- or intermediate-
risk cytogenetics (HR 0.73; 95% CI, 0.58–0.92; p =
0.007), and good performance status (HR 0.8; 95% CI,
0.64–0.99; p = 0.04), while higher recipient’s age per 10
years (HR 1.1; 95% CI, 1.02–1.18; p = 0.02) and positive
CMV serostatus of the recipient (HR 1.27; 95% CI, 1–
1.6; p = 0.04) showed worse outcome.
OS was 61% (95% CI; 58–65) for Haplo, 68% (95% CI;
62–75) for MUD, and 64% (95% CI; 56–72) for MSD (p
= 0.1) (Figure 4). Variable that independently correlated
with better OS in multivariable analysis were MAC (HR
0.76; 95% CI, 0.6–0.96; p = 0.02) and good- or
intermediate-risk cytogenetics (HR 0.7; 95% CI, 0.54–
0.9; p = 0.005), while higher recipient’s age per 10 years
was associated with poorer survival (HR 1.22; 95% CI,
1.12–1.33; p < 0.001) (Table 4).
GRFS was 46% (95% CI; 42–50) for Haplo, 42% (95%
CI; 35–50) for MUD, and 45% (95% CI; 37–53) for MSD
(p = 0.9) (Table 2). For GRFS, MAC (HR 0.79; 95% CI,
Table 2 Univariable analysis of transplants outcomes according
to donor type
Outcome* MSD MUD Haplo p
Acute GvHD, % (95% CI)
Grades II–IV 17 (12–23) 28 (22–34) 26 (23–29) 0.03
Grades III–IV 6 (4–10) 8 (5–11) 9 (7–12) 0.2
Chronic GvHD, % (95% CI)
Overall 34 (26–41) 32 (25–39) 30 (26–33) 0.3
Extensive type 14 (9–20) 18 (13–25) 10 (8–13) 0.003
NRM, % (95% CI) 10 (6–15)) 14 (9–19) 23 (20–26) < 0.001
RI, % (95% CI) 33 (26–40) 25 (19–31) 23 (20–26) 0.02
LFS, % (95% CI) 57 (49–65) 62 (55–69) 54 (51–58) 0.2
OS, % (95% CI) 64 (56–72) 68 (62–75) 61 (58–65) 0.1
GRFS, % (95% CI) 45 (37–53) 42 (35–50) 46 (42–50) 0.9
*Acute GvHD: 100-day cumulative incidence; cGvHD, NRM, and RI: cumulative
incidence at 2 years; DFS, OS, and GRFS: survival probability at 2 years
GvHD graft-versus-host disease, CI confidence interval, NRM non-relapse
mortality, RI relapse incidence, LFS leukemia-free survival, OS overall survival,
GRFS graft-versus-host disease and relapse-free survival
Table 3 Multivariable analysis of transplants outcomes according to donor type
MSD MUD Haplo
Outcome Reference HR 95% CI p HR 95% CI p
Acute GvHD
Grades II–IV 1 1.42 0.92–2.19 0.11 1.6 1.08–2.37 0.02
Grades III–IV 1 1.22 0.56–2.64 0.61 1.76 0.92-3.37 0.09
Chronic GvHD
Overall 1 0.97 0.64–1.46 0.88 1.22 0.84–1.76 0.92
Extensive type 1 0.98 0.57–1.7 0.95 0.87 0.53–1.42 0.57
NRM 1 1.38 0.73–2.6 0.3 2.6 1.5–4.49 < 0.001
RI 1 0.8 0.54–1.17 0.24 0.67 0.48–0.93 0.02
LFS 1 0.93 0.68–1.29 0.67 1.07 0.82-1.4 0.6
OS 1 0.91 0.64–1.31 0.62 1.17 0.86–1.59 0.32
GRFS 1 1.01 0.76–1.34 0.94 1.03 0.82–1.31 0.8
GvHD graft-versus-host disease, CI confidence interval, NRM non-relapse mortality, RI relapse incidence, LFS leukemia-free survival, OS overall survival, GRFS graft-
versus-host disease and relapse-free survival
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Fig. 1 Cumulative incidence of relapse according to the type of transplant
Fig. 2 Cumulative incidence of non-relapse mortality according to the type of transplant
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0.66–0.95; p = 0.01), good- or intermediate-risk cytogen-
etics (HR 0.78; 95% CI, 0.63–0.96; p = 0.02), and good
performance status (HR 0.8; 95% CI, 0.67–0.97; p =
0.02) were associated with improved outcome (Table 4).
Discussion
The use of PTCy for GvHD prophylaxis in patients with
AML in CR1 receiving SCT from MSD, MUD, and
Haplo is safe and effective, resulting in low rates of
GVHD, especially chronic, in all transplant settings.
Using this approach, our results demonstrate that pa-
tients undergoing Haplo-SCT had higher rates of
aGVHD and NRM, but lower relapse incidence. As seen
in other transplant scenarios, PB was also associated
with more GVHD and less relapse.
Due to the retrospective nature of a registry-based
study, some potential bias cannot be completely ruled
out. In order to minimize one of the most important,
such as the disease status at transplantation, all patients
included in the analysis had AML in CR1. Although all
patients received PTCy prophylaxis as the main inclu-
sion criteria for the study, a variety of conditioning regi-
mens were used and there were obvious differences in
additional GvHD prevention strategies, such as in vivo
TCD or the addition of other IS drugs, depending of the
type of donor. In fact, Haplo patients received more fre-
quently MAC, BM, and PTCy with 2 IS drugs, while a
higher proportion of MUD patients received in vivo
TCD. Although some of these variables could be ad-
justed in multivariable analysis, TCD and combination
of IS drugs for GvHD prophylaxis were strongly associ-
ated with type of donor and their effect could not be
evaluated. Despite all these pitfalls, we aimed to compare
MSD, MUD, and Haplo using a homogeneous GvHD
prophylaxis with PTCy in a large series of patients,
which allowed us to segregate the effect of donor from
the effect of GvHD prophylaxis.
PTCy was highly effective in preventing acute and
chronic GvHD in MSD, MUD, and Haplo-SCT and
Table 5 Causes of death according to donor type
Causes of death MSD
n (%)
MUD
n (%)
Haplo
n (%)
Relapse 36 (53) 31 (48) 75 (27)
Infections 10 (15) 13 (20) 107 (39)
GvHD 11 (16) 8 (12) 40 (14)
Interstitial pneumonitis 3 (4) 4 (6) 6 (2)
Sinusoidal obstruction syndrome 0 (0) 1 (2) 7 (3)
Hemorrhage 1 (1) 1 (1) 4 (1)
Secondary malignancy 0 (0) 0 (0) 6 (2)
Graft failure 0 (0) 0 (0) 5 (2)
Other 7 (10) 7 (10) 27 (10)
Fig. 3 Probability of leukemia-free survival according to the type of transplant
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seems to compare favorably with standard GvHD
prophylaxis with calcineurin inhibitor and methotrexate
in MSD and MUD transplants [24]. In fact, the inci-
dence of GvHD after PTCy seems similar to that re-
ported with anti-T cell globulin in both scenarios [25],
with the potential advantage of avoiding complications
associated with prolonged TCD. An interesting observa-
tion was the higher incidence of acute grades II–IV and
a trend towards a higher severe acute GvHD of Haplo-
SCT compared to MSD transplants. It should be noted
that most previous studies had not been able to demon-
strate this effect [9, 11, 14, 26], probably due to the use
of different GvHD prophylaxis for each procedure. In
fact, Haplo was associated with increased risk of GVHD
compared to MSD in two prospective studies using simi-
lar non-PTCy transplant platforms [16, 17]. Particularly
relevant was the low overall chronic and chronic exten-
sive GvHD observed in our study in all cohorts, as it has
been previously reported with PTCy [1, 4, 7, 24, 27]. We
should highlight that we did not observe increased risk
of chronic GvHD in Haplo in multivariable analysis. We
could speculate that PTCy abrogates the detrimental ef-
fect of HLA disparity for this particular outcome, but we
should also consider that most patients in the Haplo co-
hort received PTCy with a double combination of IS
drugs, while patients in the MSD and MUD cohorts re-
ceived less intensive GvHD prophylaxis. In fact, a recent
study of the ALWP-EBMT has recently reported that
the addition of IS drugs to PTCy enhances its effect and
reduces the risk of severe chronic GvHD, reducing mor-
tality and improving survival [6].
The most important observation from our study is that,
using PTCy as GVHD prophylaxis, NRM was higher in the
Haplo setting compared with the MSD and MUD cohorts.
Previous studies comparing Haplo (with PTCy) with MSD
and MUD transplants (with standard GvHD prophylaxis)
have reported discrepant results in terms of NRM. While
some studies reported a higher rate of NRM in Haplo [11,
15], some others reported similar [12, 14] or even improved
outcomes [10]. The reasons of these discrepancies remain
unexplained and are probably multifactorial, but differences
in transplant platforms could explain, at least in part, some
of these results. Under similar GvHD prophylaxis, a greater
HLA disparity in the Haplo compared with the MSD and
MUD settings could explain a higher NRM. This finding
suggests that HLA-matched donors, when available, should
remain as the first choice. Although the negative impact of
Haplo in NRM was partially counterbalanced with a de-
creased incidence of relapse that translated in similar LFS,
other strategies aiming at reducing relapse such as mainten-
ance or MRD-guided therapy with a growing targeted ther-
apy strategies could be investigated.
The fact that Haplo was associated with lower risk of re-
lapse deserves special attention. It is possible that this was
a spurious finding since more patients in the Haplo cohort
died from NRM and were therefore no longer at risk of
Fig. 4 Probability of overall survival according to the type of transplant
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relapse. However, Haplo procedure could have offered en-
hanced anti-leukemic efficacy, intriguingly in a way that
was independent of chronic GVHD. Superior graft-versus-
leukemia effect of Haplo compared to MSD transplants
for high-risk AML has already been observed in previous
comparative studies. Two prospective trials with biological
randomization from China showed decreased posttrans-
plant minimal residual disease (MRD) positivity [28] or re-
lapse [29] in patients undergoing Haplo, particularly
relevant for those with detectable pretransplant MRD. In
addition, a recent retrospective study of EBMT also
showed decreased relapse incidence in patients with high-
risk cytogenetics undergoing Haplo [15].
The immunological pressure of Haplo grafts has been
illustrated with the observation that loss of the mis-
matched HLA haplotype is a frequent mechanism of es-
cape associated with relapse [30]. The biological
explanation is unknown but NK-mediated alloreactivity
has been previously proposed to induce enhanced effi-
cacy and GVHD protection in the context of T cell-
depleted Haplo-SCT [31]. The hypothesis of an in-
creased anti-leukemic efficacy independent of GvHD of
Haplo-SCT compared to matched donors in the context
of PTCy should be further explored from a clinical and
biological point of view.
Despite the risks and benefits of BM over PB have
been widely investigated, the effect of the stem cell
source on transplant outcomes deserves special consid-
eration. In MUD transplants, BM reduced the risk of
chronic GVHD in a randomized study [32] and im-
proved long-term GRFS and overall survival in a large
retrospective registry study [33]. In Haplo-SCT, the use
of PB resulted in an increased risk of acute GvHD, un-
certain impact of chronic GvHD, and decreased risk of
relapse in patients with acute leukemia, but not with
lymphoma [34, 35]. In the present study, we confirm
that PB was associated with increased risk of acute and
chronic GvHD, less relapses, but no final influence on
NRM and survival.
Although most retrospective studies comparing
MAC with RIC in patients with AML have suggested
similar survival, since the latter has been associated
with increased relapse but reduced NRM [36, 37], we
observed a significant reduction of relapse with MAC
that translated into improved survival when compared
with RIC. Unfortunately, the only randomized study,
designed to address this issue in patients with AML,
was closed to patient accrual early due to excess of
relapse and reduced survival in the RIC cohort [38].
Since the efficacy of RIC in SCT mainly relies on
graft-versus-leukemia effect, it may be particularly
relevant to increase conditioning intensity in trans-
plant platforms with effective GvHD control such as
with the use of PTCy.
Conclusion
In patients with AML undergoing allo-SCT, PTCy for
GvHD prophylaxis showed promising outcomes. Future
studies comparing PTCy standard regimens are war-
ranted to establish the standard of care. In this specific
scenario, Haplo-SCT had increased risk of acute GVHD
and NRM that was counterbalanced by a lower relapse
incidence that translated into no significant difference in
LFS and OS. Haplo-SCT offers a good alternative to
matched donor transplants.
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